Evonik stock falls pre-market: drug-delivery group at EUR 21.15
Published on 10/19/2026 at 08:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBusiness model and reporting date
- The group supplies lipid-based drug-delivery products and services to pharmaceutical and biotechnology customers.
- Evonik is scheduled to report its third-quarter 2026 business development on November 3, 2026.
- Evonik stock trades pre-market at EUR 21.15 at 8:13 a.m. CEST at Lang & Schwarz on October 19, 2026, 1.26 percent below the Xetra close of October 16, 2026.
Evonik serves pharmaceutical and biotechnology customers with lipid-based drug-delivery products and services. Evonik stock trades pre-market at EUR 21.15 at 8:13 a.m. CEST at Lang & Schwarz on October 19, 2026, 1.26 percent below the Xetra close of October 16, 2026 (EUR 21.42).
Ahead of the Xetra open
The current indication is EUR 0.27 below the Xetra close of October 16, 2026. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Evonik stock.
Business and reporting agenda
Evonik develops products for pharmaceutical and biotechnology customers, including materials used in lipid-based drug delivery, according to its investor-relations information. The company is scheduled to report on its third-quarter 2026 business development on November 3, 2026. Market context: Market report DAX.
